National Vaccine Advisory Committee
Executive Summary
Will meet June 14-15 to discuss new vaccine development and licensure, vaccine adverse events, testing, post-marketing surveillance, the 1990 National Vaccine Report to Congress and the National Vaccine Plan. Meeting begins at 9 a.m. on the first day and 8:30 a.m. on the second at HHS' Hubert Humphrey Building, Room 703A, 200 Independence Ave. S.W., Washington, D.C.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.